Our Offer
MAVIE advises Western healthcare companies on
M&A, licensing, equity or Joint-Venture transactions in China.
Licensing services
You need cash to fuel your clinical studies and reach your development milestones before you exit with a trade sale to a major Western player. License out your technology to a Chinese player for non-dilutive financing and focus your efforts on the US and European markets.
Equity plus China
You recognize that China can help you increase your global market share, accelerate your product development and reduce your cost of goods sold in addition to provide financial resources for your aspirations.
Find that outstanding partner and embark on a strategic partnership.
M&A
- Increase your exit options and add China buyers to your M&A list.
- Include the China market opportunity and COGS reduction in your valuation model
- Or alternatively, work on a Management Buy-Out with a Chinese Private Equity and add Hong Kong IPO to your list of exit options
Why Mavie?
- Unique focus on MedTech: we have our own vision of the future of MedTech
- Strong track record: we are #1 in China in terms of number of cross-border MedTech deals
- Privileged relationships & insider access in China: we understand China MedTech from the people leading that industry
- High work standards and high conversion rate: we are committed to your success with 80% success rate